CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 142 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,692 | -36.9% | 650 | -50.0% | 0.00% | – |
Q2 2023 | $15,359 | +86.4% | 1,300 | +100.0% | 0.00% | – |
Q1 2023 | $8,242 | +39147.6% | 650 | -60.6% | 0.00% | -100.0% |
Q4 2022 | $21 | -99.9% | 1,650 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $21,000 | 0.0% | 1,650 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $21,000 | -27.6% | 1,650 | -28.3% | 0.00% | – |
Q1 2022 | $29,000 | +1350.0% | 2,300 | +253.8% | 0.00% | – |
Q4 2021 | $2,000 | 0.0% | 650 | 0.0% | 0.00% | – |
Q3 2021 | $2,000 | -33.3% | 650 | 0.0% | 0.00% | – |
Q2 2021 | $3,000 | 0.0% | 650 | 0.0% | 0.00% | – |
Q1 2021 | $3,000 | -25.0% | 650 | 0.0% | 0.00% | – |
Q4 2020 | $4,000 | -20.0% | 650 | 0.0% | 0.00% | – |
Q3 2020 | $5,000 | – | 650 | – | 0.00% | – |
Q2 2020 | $0 | – | 0 | – | 0.00% | – |
Q1 2020 | $0 | – | 0 | – | 0.00% | – |
Q4 2019 | $0 | – | 0 | – | 0.00% | – |
Q3 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
Q4 2018 | $8,000 | -27.3% | 1,020 | 0.0% | 0.00% | – |
Q3 2018 | $11,000 | -15.4% | 1,020 | +2.0% | 0.00% | -100.0% |
Q2 2018 | $13,000 | -71.7% | 1,000 | -80.0% | 0.00% | -50.0% |
Q1 2018 | $46,000 | 0.0% | 5,000 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $46,000 | +15.0% | 5,000 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $40,000 | +73.9% | 5,000 | +25.0% | 0.00% | +100.0% |
Q2 2017 | $23,000 | – | 4,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |